var data={"title":"Mivacurium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mivacurium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6598?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">see &quot;Mivacurium: Drug information&quot;</a> and <a href=\"topic.htm?path=mivacurium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mivacurium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49411700\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mivacron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060432\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Neuromuscular Blocker Agent, Nondepolarizing</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Skeletal Muscle Relaxant, Paralytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060425\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">see &quot;Mivacurium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Titrate dose to effect; dose must be individualized due to interpatient variability. Obese patients (weighing &ge;30% IBW) should be dosed on IBW.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adjunct to surgical anesthesia (neuromuscular blockade): Note: </b>Due to pharmacodynamics differences in pediatric patients than adults, children 2 to 12 years require a higher mg/kg dose and often more frequent repeat maintenance dosing or higher continuous infusion rates.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV bolus: 0.2 mg/kg over 5 to 15 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: Usual dose: 14 <b>mcg</b>/kg/<b>minute</b> (0.84 <b>mg</b>/kg/<b>hour</b>); range: 5 to 31 <b>mcg</b>/kg/<b>minute </b>(0.3 to 1.86 <b>mg</b>/kg/<b>hour</b>); begin infusion upon evidence of spontaneous recovery from initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV bolus: Initial: 0.15 mg/kg over 5 to 15 seconds, <b>or</b> 0.2 mg/kg over 30 seconds, <b>or </b>a total bolus of 0.25 mg/kg divided into 2 doses (0.15 mg/kg followed in 30 seconds by 0.1 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Maintenance:</i> 0.1 mg/kg at ~15-minute intervals; begin upon evidence of spontaneous recovery from initial bolus</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Burn patients</i>: Administer test dose of 0.015 to 0.02 mg/kg, then follow with appropriate dosing and monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Cardiovascular disease (clinically significant) or increased sensitivity to release of histamine (eg, asthma):</i> Initial: &le;0.15 mg/kg over 60 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: Initial: 9 to 10 <b>mcg</b>/kg/<b>minute</b> (0.54 to 0.6 <b>mg</b>/kg/<b>hour</b>); begin infusion upon evidence of spontaneous recovery from initial bolus dose. Usual infusion rate: 5 to 7 <b>mcg</b>/kg/<b>minute</b> (0.3 to 0.42 <b>mg</b>/kg/<b>hour</b>) under balanced anesthesia; range: 1 to 15 <b>mcg</b>/kg/<b>minute</b> (0.06 to 0.9 <b>mg</b>/kg/<b>hour</b>). <b>Note: </b>A lower initial infusion rate (eg, 4 <b>mcg</b>/kg/<b>minute </b>[0.24 <b>mg</b>/kg/<b>hour</b>]) should be used if started simultaneously with initial bolus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ICU paralysis (eg, facilitate mechanical ventilation) in select adequately sedated patients: </b>Limited data available in ages &lt;2 years (Martin 1999):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: IV: Initial bolus: 0.2 mg/kg, followed by continuous IV infusion of 10 <b>mcg</b>/kg/<b>minute</b> (0.6 <b>mg</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: IV: Initial bolus: 0.2 mg/kg, followed by continuous IV infusion of 16 <b>mcg</b>/kg/<b>minute</b> (0.96 <b>mg</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IV: Initial bolus: 0.2 mg/kg, followed by continuous IV infusion of 7 <b>mcg</b>/kg/<b>minute</b> (0.42 <b>mg</b>/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult: <b>Neuromuscular blockade:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV bolus: Initial: 0.15 mg/kg over 5 to 15 seconds, <b>or</b> 0.2 mg/kg over 30 seconds, <b>or </b>0.25 mg/kg in divided doses (0.15 mg/kg followed in 30 seconds by 0.1 mg/kg); maintenance: 0.1 mg/kg at ~15-minute intervals</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Burn patients: Administer test dose of 0.015 to 0.02 mg/kg, then follow with appropriate dosing and monitoring</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular disease (clinically significant) or increased sensitivity to release of histamine (eg, asthma): Initial: &le;0.15 mg/kg over 60 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initial: 9 to 10 <b>mcg</b>/kg/<b>minute</b> (0.54 to 0.6 <b>mg</b>/kg/<b>hour</b>) upon evidence of spontaneous recovery from initial bolus dose. Usual infusion rate: 5 to 7 <b>mcg</b>/kg/<b>minute</b> under balanced anesthesia. <b>Note:</b> If continuous infusion is initiated simultaneously with the initial dose, a lower initial infusion rate should be used (eg, 4 <b>mcg</b>/kg/<b>minute</b>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for concomitant inhalational anesthetics at steady state: </b>Children &ge;2 years and Adolescents: Consider reduction of mivacurium continuous infusion rate by &le;35% to 40% and/or a reduction of bolus dose by &le;25% when administered concomitantly with isoflurane or enflurane at steady state; greater reductions may be necessary with higher concentrations of isoflurane or enflurane. Consider smaller reduction of mivacurium dosage with concomitant halothane administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: Mild to severe impairment: IV: Initial bolus: 0.15 mg/kg; subsequent dosing is based on clinical response. No adjustment of infusion rates is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: Mild to severe impairment: IV: Initial bolus: 0.15 mg/kg; subsequent dosing is based on clinical response. Decrease infusion rates by as much as 50% (dependent on the degree of hepatic impairment).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159483\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no pediatric specific recommendations; based on experience in adult patients, consider bolus dose adjustment; subsequent dosing based on clinical response and no adjustment of infusion rates is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159484\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no pediatric specific recommendations; based on experience in adult patients, consider bolus dose adjustment; subsequent dosing based on clinical response and consider dosing adjustment of infusion (dependent on the degree of hepatic impairment).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197742\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">see &quot;Mivacurium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuromuscular blockade:</b> IV: Dose to effect; doses must be individualized due to interpatient variability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent bolus: Initial: 0.15 mg/kg over 5 to 15 seconds, <b>or</b> 0.2 mg/kg over 30 seconds, <b>or </b>0.25 mg/kg in divided doses (0.15 mg/kg followed in 30 seconds by 0.1 mg/kg); maintenance: 0.1 mg/kg at ~15 minute intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Burn patients: Administer test dose of 0.015 to 0.02 mg/kg, then follow with appropriate dosing and monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular disease (clinically significant) or increased sensitivity to release of histamine (eg, asthma): Initial: &le;0.15 mg/kg over 60 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous infusion: Initial: 9 to 10 <b>mcg</b>/kg/<b>minute</b> (0.54 to 0.6 <b>mg</b>/kg/<b>hour</b>) upon evidence of spontaneous recovery from initial bolus dose. Usual infusion rate:  5 to 7 <b>mcg</b>/kg/<b>minute</b> under balanced anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If continuous infusion is initiated simultaneously with the initial dose, a lower initial infusion rate should be used (eg, 4 <b>mcg</b>/kg/<b>minute</b>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant inhalational anesthetics at steady state:</b> Consider reduction of mivacurium continuous infusion rate by &le;35% to 40% or a reduction of bolus dose by &le;25% with concomitant isoflurane or enflurane at steady state; greater reductions may be necessary with higher concentrations of isoflurane or enflurane. Consider small reduction of mivacurium dosage with concomitant halothane administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991296\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Mild to severe impairment: IV: Initial bolus: 0.15 mg/kg; subsequent dosing is based on clinical response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50988615\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Mild to severe impairment: IV: Initial bolus: 0.15 mg/kg; subsequent dosing is based on clinical response. Decrease infusion rates by as much as 50% (dependent on the degree of hepatic impairment).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49411627\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mivacron: 10 mg/5 mL (5 mL); 20 mg/10 mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060435\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV bolus:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 12 years: Administer undiluted over 5 to 15 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents and Adults: Administer undiluted over 5 to 30 seconds; the specific rate depends on dose to prevent hemodynamic effects</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Further dilute and administer via an infusion pump; use infusion solutions within 24 hours of preparation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197734\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 25&deg;C (77&deg;F);.excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Do not freeze.  Mivacurium diluted to 0.5 mg/mL in D5W, D5NS, NS, LR, or D5LR in PVC bags is stable at 5&deg;C to 25&deg;C (41&deg;F to 77&deg;F) for up to 24 hours. Discard unused portion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060434\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in ages &ge;2 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197783\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mivacron may be confused with Mevacor</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49269426\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, hypotension (dosage and time dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactoid reaction, anaphylaxis, bradycardia, bronchospasm, cardiac arrhythmia, delayed recovery from neuromuscular block (prolonged effect), dizziness, drug tolerance (diminished effect), erythema, hypersensitivity reaction, hypoxemia, injection site reaction, muscle spasm, phlebitis, skin rash, tachycardia, urticaria, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197725\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mivacurium or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for neuromuscular blockers is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197711\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Severe anaphylactic reactions  have been reported (some life-threatening and fatal). Appropriate emergency treatment (including epinephrine 1 mg/mL) should be immediately available during use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bradycardia: Does not counteract bradycardia produced by anesthetics/vagal stimulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Burn injury: Resistance may occur in burn patients (&ge;20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009). These patients may require increased doses or patients may also have reduced plasma cholinesterase activity, requiring dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with clinically significant cardiovascular disease; reduce initial dosage and inject slowly (over 60 seconds). Carefully monitor hemodynamic status and maintain adequate hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions which may antagonize neuromuscular blockade: Acid-base and/or electrolyte abnormalities,  demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (ACCM/SCCM/ASHP [Murray 2002]; Greenberg 2013; Miller 2010; Naguib 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions which may diminish plasma cholinesterase activity: Plasma cholinesterase genetic abnormalities, malignant tumors, infections, anemia, decompensated heart disease, peptic ulcer, and myxedema may diminish plasma cholinesterase activity and result in prolonged neuromuscular blockade.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions which may potentiate neuromuscular blockade: Acid-base and/or electrolyte abnormalities, cachexia, carcinomatosis, debilitation, neuromuscular diseases, Eaton-Lambert syndrome, myasthenia gravis, and myasthenic syndrome may result in potentiation of neuromuscular blockade (Greenberg 2013; Miller 2010; Naguib 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; prolonged neuromuscular block may occur. Reduced plasma cholinesterase activity may occur in patients with renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; prolonged neuromuscular block may occur. Markedly reduced  plasma cholinesterase activity may occur in patients with chronic hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; effects and duration are more variable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immobilized patients: Resistance may occur in patients who are immobilized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Histamine release: Use with caution in patients in whom substantial histamine release would be potentially hazardous (eg, asthma); reduce initial dosage and inject slowly (over 60 seconds). Carefully monitor hemodynamic status and maintain adequate hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homozygous for atypical plasma cholinesterase gene: Use with extreme caution if at all in patients homozygous for the atypical plasma cholinesterase gene; extremely sensitive to the neuromuscular blocking effect of mivacurium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in obese patients (weight &ge;30% than their ideal body weight [IBW]); determine initial dose using the patient&rsquo;s IBW.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical. Does not relieve pain or produce sedation; use should include appropriate anesthesia, pain control, and sedation. Use of a peripheral nerve stimulator to monitor drug effects is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50577559\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In children 2 to 12 years, mivacurium produces minimal hemodynamic changes (MAP, HR) at usual doses; however, higher doses (&gt;0.2 mg/kg) may produce transient decreases in MAP. In adults, the decreased MAP was observed 1 to 3 minutes postdose and associated with histamine release with resolution in an additional 1 to 3 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46553913\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197714\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114799&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Neuromuscular-Blocking Agents may diminish the therapeutic effect of Amifampridine. Amifampridine may diminish the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May increase the serum concentration of Mivacurium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echothiophate Iodide: May increase the serum concentration of Mivacurium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Mivacurium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenelzine: May increase the serum concentration of Mivacurium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: May increase the serum concentration of Mivacurium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49366882\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46715645\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Plasma cholinesterase concentrations are decreased in pregnancy; neuromuscular blockade may be prolonged and intensified. Use in cesarean section has been reported; adjustment of the dose may be necessary (Kim 1999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060431\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Peripheral nerve stimulator measuring twitch response, heart rate, blood pressure, assisted ventilation status</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197710\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antagonizes acetylcholine by competitively binding to cholinergic sites on motor endplates in skeletal muscle. This inhibits contractile activity in skeletal muscle leading to muscle paralysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197724\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Neuromuscular blockade (dose dependent): IV: Adults: 1.5 to 3 minutes; Elderly: 1.5 minutes slower; Children 2 to 12 years of age: Faster than adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak: Neuromuscular blockade (dose dependent): IV: Children 2 to 12 years of age: Median range: 1.6 to 2.8 minutes; Adults: Median range: 2.3 to 4.9 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Short due to rapid hydrolysis by plasma cholinesterases; duration may be slightly longer in the elderly; may also be longer in patients with hepatic or renal impairment and patients with reduced plasma cholinesterase (pseudocholinesterase) activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Clinically effective block may last 10 minutes (6 to 15 minutes) with 95% spontaneous recovery in 14 to 26 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult: Clinically effective block may last for 15 to 20 minutes; spontaneous recovery may be 95% complete in 21 to 34 minutes (dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d </sub>(mean):147 to 274 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Enzymatic hydrolysis via plasma cholinesterase, inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~7% as unchanged drug; Cook 1992) and bile</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51159662\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: Duration is ~1.5 times longer in patients with ESRD.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic function impairment: Duration is ~3 times longer in patients with end-stage hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Onset and recovery rate are faster and duration is shorter in children 2 to 12 years of age. In children 2 to 12 years of age when used as adjunct to general anesthesia (nitrous oxide/oxygen/opioid), typical intermittent IV doses produced a maximum effect at a mean 1.9 minutes (range: 1.3 to 3.3 minutes) and a clinically effective blockade for a mean of 10 minutes (range: 6 to 15 minutes).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Geriatric: Onset and recovery rate may be slower and duration may be longer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49656662\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Mivacron Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (5 mL): $27.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $35.86</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038704\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Mivacron (AE, AR, AT, AU, BB, BE, BG, BH, BM, BS, BZ, CH, CL, CN, CY, CZ, DE, DK, EG, ES, FI, FR, GB, GY, HK, HN, HU, IE, IL, IQ, IR, IT, JM, JO, KR, KW, LB, LT, LU, LY, MT, MY, NL, NO, OM, PL, PT, PY, QA, RO, SA, SE, SG, SI, SR, SY, TT, UY, YE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cook DR, Freeman JA, Lai AA, et al, &ldquo;Pharmacokinetics of Mivacurium in Normal Patients and in Those With Hepatic or Renal Failure,&rdquo; <i>Br J Anaesth</i>, 1992, 69(6):580-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin LD, Bratton SL, O'Rourke PP. Clinical uses and controversies of neuromuscular blocking agents in infants and children. <i>Crit Care Med</i>. 1999;27(7):1358-1368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mivacurium-pediatric-drug-information/abstract-text/10446832/pubmed\" target=\"_blank\" id=\"10446832\">10446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mivacron injection (mivacurium) [prescribing information]. North Chicago, IL: Abb Vie Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo; <i>Crit Care Med</i>, 2002, 30(1):142-56. Available at: http://www.sccm.org/pdf/NeuromuscularBlockade.pdf. Accessed August 6, 2003.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114799 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F49411700\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060432\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1060425\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51159483\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51159484\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F197742\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991296\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50988615\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F49411627\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060435\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F197734\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060434\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F197783\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F49269426\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F197725\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F197711\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F50577559\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46553913\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F197714\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F49366882\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46715645\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060431\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F197710\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F197724\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51159662\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F49656662\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038704\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/114799|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mivacurium-drug-information\" class=\"drug drug_general\">Mivacurium: Drug information</a></li><li><a href=\"topic.htm?path=mivacurium-patient-drug-information\" class=\"drug drug_patient\">Mivacurium: Patient drug information</a></li></ul></div></div>","javascript":null}